Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I, Dose-Escalation Study Evaluating The Safety And Tolerability Of Gdc-0853 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia

NCT01991184 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01991184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01991184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I, Dose-Escalation Study Evaluating The Safety And Tolerability Of Gdc-0853 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 16, 2013
Completion date
March 8, 2022
Enrollment
24 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, chronic, diffuse large b-cell lymphoma